Valuation: Lifecare ASA

Market Cap 8.85Cr 92.02L 80.94L 75.19L 69.15L 1.3Cr 89Cr 1.32Cr 8.99Cr 3.51Cr 43Cr 3.45Cr 3.38Cr 150.8Cr P/E 2026 *
-0.78x
P/E 2027 * -1.06x
Enterprise Value 12Cr 1.29Cr 1.14Cr 1.06Cr 97.27L 1.82Cr 125.35Cr 1.86Cr 13Cr 4.93Cr 61Cr 4.86Cr 4.75Cr 212.12Cr EV / Sales 2026 *
-
EV / Sales 2027 * 25.3x
Free-Float
89.66%
Yield 2026 *
-
Yield 2027 * -
1 day-4.56%
1 week-4.56%
Current month-14.78%
1 month-14.78%
3 months-31.93%
6 months-59.64%
Current year-92.94%
1 week 0.28
Extreme 0.2825
0.28
1 month 0.28
Extreme 0.2825
0.3
Current year 0.28
Extreme 0.2825
0.9
1 year 0.28
Extreme 0.2825
18.1
3 years 0.28
Extreme 0.2825
18.1
5 years 0.28
Extreme 0.2825
18.1
10 years 0.28
Extreme 0.2825
18.1
Manager TitleAgeSince
Chief Executive Officer 50 07/09/2020
Director of Finance/CFO - 01/04/2026
Corporate Officer/Principal - 01/03/2024
Director TitleAgeSince
Director/Board Member - 26/06/2020
Chairman - 08/05/2021
Director/Board Member - 20/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-4.56%-4.56% - - 92.02L
+1.13%-3.59%-3.35%+12.75% 4.63TCr
+3.13%+5.34%+402.93%+605.08% 4.01TCr
+2.14%+2.95%+10.83%+65.45% 3.63TCr
+4.43%-1.51%+6.73%-9.17% 3.46TCr
+1.23%-2.05%+0.56%+30.76% 2.68TCr
+0.29%-2.75% - - 1.67TCr
+14.71%+12.62%+38.50%+146.99% 1.69TCr
+1.18%-4.81%+1.52%+9.31% 1.31TCr
+1.82%+0.19%+1.45%-30.74% 1.3TCr
Average +2.40%+0.47%+57.40%+103.80% 2.71TCr
Weighted average by Cap. +2.77%+0.23%+76.35%+131.88%

Financials

2026 *2027 *
Net sales - 50L 5L 5L 4L 4L 7L 5.03Cr 7L 50.77L 19.8L 2.45Cr 19.51L 19.09L 8.52Cr
Net income -8.6Cr -89.38L -78.61L -73.03L -67.17L -1.26Cr -87Cr -1.28Cr -8.73Cr -3.41Cr -42Cr -3.36Cr -3.28Cr -146.47Cr -8.2Cr -85.23L -74.96L -69.63L -64.04L -1.2Cr -83Cr -1.22Cr -8.33Cr -3.25Cr -40Cr -3.2Cr -3.13Cr -139.66Cr
Net Debt 3.6Cr 37.42L 32.91L 30.57L 28.12L 52.73L 36Cr 53.67L 3.66Cr 1.43Cr 18Cr 1.4Cr 1.37Cr 61Cr 3.8Cr 39.49L 34.74L 32.27L 29.68L 55.66L 38Cr 56.66L 3.86Cr 1.51Cr 19Cr 1.48Cr 1.45Cr 65Cr
Logo Lifecare ASA
Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.
Employees
25
Date Price Change Volume

Annual profits - Rate of surprise